School of Medicine, Tehran University of Medical Sciences (TUMS), Children's Medical Center Hospital, Dr. Qarib St., Keshavarz Blvd, Tehran14194, Iran.
Universal Scientific Education and Research Network (USERN), Tehran, Iran.
Rev Neurosci. 2020 Nov 2;32(2):191-202. doi: 10.1515/revneuro-2020-0062. Print 2021 Feb 23.
Vascular endothelial growth factor (VEGF) has a crucial role in the angiogenesis of various tumors, including glioma. As the levels of VEGF would change in patients with glioma, we conducted the current systematic review and meta-analysis to more clearly determine the VEGF level alterations in different grades of glioma. PubMed and Scopus databases were sensitively searched for all the possible keywords addressing glioma and VEGF. Case-control and cohort studies on human subjects, which measured VEGF levels were eligible to be included in the study. Out of a total number of 3,612 studies, 22 studies were included and 12 studies entered the meta-analysis. This review revealed that serum levels of VEGF in glioma patients were 1.56 pg/dL higher compared to healthy controls ( = 0.05). Besides, immunohistochemistry (IHC) measurement of VEGF in surgical biopsies indicated significant difference in these two groups as well ( = 0.02). Yet, there was not a significant difference between patients with low-grade gliomas (World Health Organization (WHO) grades I-II, LGG) and those with high-grade gliomas (WHO grades III-IV, HGG) ( = 0.43). The results of this systematic review and meta-analysis demonstrate that VEGF levels would significantly increase in glioma, and therefore, could be potentially considered as a biomarker for this cancer.
血管内皮生长因子 (VEGF) 在包括神经胶质瘤在内的各种肿瘤的血管生成中起着关键作用。由于神经胶质瘤患者的 VEGF 水平会发生变化，因此我们进行了这项系统评价和荟萃分析，以更清楚地确定不同级别神经胶质瘤中 VEGF 水平的变化。我们在 PubMed 和 Scopus 数据库中使用了所有可能的关键字来搜索有关神经胶质瘤和 VEGF 的研究。纳入研究的标准为：针对人类受试者，测量 VEGF 水平的病例对照和队列研究。在总共 3612 项研究中，有 22 项研究符合纳入标准，其中 12 项研究纳入荟萃分析。这项综述表明，与健康对照组相比，神经胶质瘤患者的血清 VEGF 水平高 1.56 pg/dL（=0.05）。此外，手术活检中 VEGF 的免疫组织化学（IHC）测量也表明这两组之间存在显著差异（=0.02）。然而，低级别神经胶质瘤（世界卫生组织 [WHO] 分级 I-II 级，LGG）患者和高级别神经胶质瘤（WHO 分级 III-IV 级，HGG）患者之间没有显著差异（=0.43）。这项系统评价和荟萃分析的结果表明，VEGF 水平在神经胶质瘤中会显著升高，因此，VEGF 可能被认为是这种癌症的潜在生物标志物。
